THE-BMB-GROUP
2.10.2015 09:01:16 CEST | Business Wire | Pressemeddelelse
The BMB Group, founded in 2006 by members of Asian and Gulf based ruling families, has refocused its business to provide capital and specialist advice exclusively for Forbes 500 families. As part of these changes, former Chairman and CEO Rayo Withanage has handed the reigns of BMB to Mr Rahula Withanage as he moves on to run Scepter Partners with Anthony J. Steains and his former Blackstone Asia Advisory Partners team.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151002005056/en/
Though no longer part of BMB’s management, Mr Rayo Withanage will still retain an important role in the future of BMB as one of its investors. Scepter has committed $2 billion for BMB to develop transactions and operating businesses that can be meaningful and transformative for Forbes 500 families. Commenting on the split co-founder and owner HH Prince Abdul Ali Yil Kabier, a scion of the ruling family of Brunei commented “We hope that some of BMB’s activities may generate investment opportunities for Scepter as a co-investor in the future. Scepter seeks to maintain a good working relationship with BMB in instances where large commitments may be required."
As the new CEO of BMB, Mr Rahula Withanage added, "BMB is committed to servicing its present partners and growing its capabilities in its specialization under independent management and governance. BMB will continue to deepen partnerships with some of the largest family offices in the world, where these partners wish to develop new business lines and grow existing businesses, particularly in natural resources, real estate, hospitality, and media and technology. BMB is particularly focused on situations where partners wish to buy out minority stakeholders, consolidate controlling positions and obtain expansion capital for the acquisition of new businesses.”
In addition to providing capital solutions BMB will continue to provide specialist advice in the form of business development and strategic advisory services, with a focus on emerging markets of Asia, Latin America, CIS and the Middle East. We exist to make a meaningful contribution to the endeavors of our family partners.
About The BMB Group
BMB was founded by financier Rayo Withanage and HH Prince Abdul Ali Yil Kabier as a commercial multi-family office of ruling families and ultra-high net worth investors. The firm was advised by Blackstone Advisory Partners for four years before spinning out its family office assets into Scepter Partners under independent management by Mr Anthony Steains.
The spin out was driven by the interests of investors to convert from a traditional family office structure to a more institutionalized merchant banking and direct investment syndicate characterized by Scepter Partners. BMB has since focused its business to be an advisor with a specific focus on Forbes 500 investors which only include family offices with over $5 billion in assets. BMB assists its partners to enhance M&A activity and catalyze transformative transactions that leverage off of BMB’s expertise and experience in government relations, strategic advisory and corporate finance. BMB is headquartered in Bermuda with representative offices in London and Monaco.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151002005056/en/
Contact:
The BMB Group
Josephine Kime, +1-212-317-8800
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum